Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jan;21(1):96-103.
doi: 10.1016/j.jcf.2021.07.003. Epub 2021 Jul 19.

Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation

Gregory S Sawicki  1 , Kate Van Brunt  2 , Jason Booth  2 , Evan Bailey  2 , Stefanie J Millar  3 , Michael W Konstan  4 , Patrick A Flume  5
Affiliations
Observational Study

Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation

Gregory S Sawicki et al. J Cyst Fibros. 2022 Jan.

Abstract

Background: People with cystic fibrosis (CF) heterozygous for F508del-CFTR and a minimal function CFTR mutation (F/MF) that results in no CFTR protein or results in CFTR protein that is not responsive to tezacaftor, ivacaftor, and tezacaftor/ivacaftor in vitro comprise a sizeable percentage of the US CF population. This retrospective, cross-sectional, observational study aimed to characterize CF burden in this subpopulation.

Methods: People ≥2 years of age in the US CF Foundation Patient Registry with a CF diagnosis, F/MF genotype, and ≥1 encounters in 2017 were included. Descriptive analyses assessed lung function, nutritional parameters, microbiology, hospitalization and pulmonary exacerbation rates, and CF-related complications. Results were stratified by age group; select characteristics were summarized by percent predicted FEV1 (ppFEV1) and ethnicity.

Results: 5348 people met inclusion criteria. Rates of positive bacterial cultures, pulmonary exacerbations, and hospitalizations were generally higher in older age groups. Prevalence of prescribed symptomatic CF therapies was substantial and also generally higher in older age groups. ppFEV1 was lower in older age groups. A greater percentage of adolescents and adults reported complications, including cirrhosis, osteoporosis, osteopenia, and sinus disease, than younger age groups. Increased prevalence of cultured Pseudomonas aeruginosa and prescribed chronic therapy was seen with decreasing ppFEV1. In each age group, ppFEV1 was slightly higher in the non-Hispanic cohort than in the Hispanic cohort.

Conclusions: People with F/MF genotypes have substantial disease burden that worsened in older age groups consistent with the progressive nature of CF, indicating need for additional treatment options in this subpopulation.

Keywords: Cystic fibrosis; F508del-CFTR; Minimal function; Observational study.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All authors received nonfinancial assistance (assistance with manuscript preparation) from ArticulateScience LLC, which received funding from Vertex Pharmaceuticals Incorporated. Additional disclosures are as follows: GSS reports personal fees from Vertex; KVB and JB are employees of Vertex and may own stock or stock options in Vertex; EB is a former employee of Vertex and may own stock or stock options in the company; SJM is an employee of ICON Clinical Research, which received funding from various pharmaceutical, biotechnology, and device companies for providing clinical research services and received funding from Vertex for analytical services during the conduct of this study; MWK reports grants and personal fees from Vertex; PAF reports grants and personal fees from Vertex.

Figures

Figure 1.
Figure 1.. Microbiology for 2017 by age groupa
B., Burkholderia; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; P., Pseudomonas; S., Stenotrophomonas. a Based on evaluable people; denominator for percentage calculation excludes missing values.
Figure 2.
Figure 2.. Select chronic therapies for 2017 by age groupa
a Based on evaluable people; denominator for percentage calculation excludes missing values. Pancreatic enzymes and inhaled bronchodilators were prescribed in nearly all people with CF.
See this image and copyright information in PMC

References

    1. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891–904. - PubMed
    1. Clancy JP. Rapid therapeutic advances in CFTR modulator science. Pediatr Pulmonol 2018;53:S4–S11. - PMC - PubMed
    1. Kerem E, Corey M, Kerem BS, et al. The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508). N Engl J Med 1990; 323:1517–22. - PubMed
    1. Johansen HK, Nir M, Hoiby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet 1991;337:631–4. - PubMed
    1. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019;381:1809–19. - PMC - PubMed

Publication types

Substances